title: Intravesical BCG treatment for superficial bladder cancer: long-term results using two different strains of BCG.
abstract: A total of 21 patients received intravesical BCG for the prevention of recurrence of superficial transitional cell carcinoma of the bladder. Twelve patients received the Glaxo strain and 9 the Pasteur strain of the bacillus. Although thought to have different anti-tumour activities owing to a difference in antigenicity, these 2 strains produced similar tumour-free rates at 5 years' mean follow-up with an overall tumour-free rate of 43%.
authors.affiliation: Department of Urology, Royal Infirmary, Bristol.
authors.forename: A
authors.initials: A
authors.lastname: Mukherjee
authors.forename: R
authors.initials: R
authors.lastname: Persad
authors.forename: P J
authors.initials: PJ
authors.lastname: Smith
mesh_terms: D000283:Administration, Intravesical; D001500:BCG Vaccine / Q000008:administration & dosage* / Q000145:classification / Q000276:immunology; D002295:Carcinoma, Transitional Cell / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D001749:Urinary Bladder Neoplasms / Q000628:therapy*
chemical_list: D001500:BCG Vaccine